|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
|
| Rank | Ticker | Real Mentions | Prev Rank |
|---|---|---|---|
| 1 | AMC | 1,540 (11%) | 3 ⬆️ |
| 2 | BB | 1,018 (7%) | 1 ⬇️ |
| 3 | WISH | 859 (6%) | 2 ⬇️ |
| 4 | CLNE | 765 (5%) | 13 ⬆️⬆️ |
| 5 | GME | 572 (4%) | 4 ⬇️ |
| 6 | UWMC | 538 (4%) | 6 ➖ |
| 7 | CLOV | 482 (3%) | 7 ➖ |
| 8 | PLTR | 457 (3%) | 15 ⬆️⬆️ |
| 9 | CLF | 413 (3%) | 10 ⬆️ |
| 10 | SPY | 312 (2%) | 9 ⬇️ |
Not much on the scanner
| ANPC [NASD] |
| AnPac Bio-Medical Science Co., Ltd. |
| Healthcare | Biotechnology | China |
+21% 13M Float 56M MC
June 18, 2021 09:22 AM ET (BZ Newswire) -- Biotech
- AnPac Bio-Medical Science Co Ltd (NASDAQ:ANPC) has received its first disease treatment patent by the United States Patent and Trademark Office.
- The patent covers novel medical devices for both disease detection and treatment applications and has 25 claims.
- The patent covers novel device structures and methods to modify biological samples for treatment purposes. This latest patent is the 21st patent granted to AnPac Bio in the U.S.
- The Company also announced that its newly launched cancer treatment joint venture has secured, via signed legal documents, over $4 million of capital contributions from multiple funding sources.
- The funding will be used to fabricate cancer treatment medical devices and the device's subsequent laboratory tests this year.
- Price Action: ANPC shares are up 21.9% at $5.29 during the premarket trading session on the last check Friday.
FORGOT TO DRAW IN DAILING RESISTANCE PRE MARKET
ALWAYS ZOOM OUT ON THE DAILY
